Tactics with Prebiotics for the Treatment of Metabolic Dysfunction-Associated Fatty Liver Disease via the Improvement of Mitophagy

Int J Mol Sci. 2023 Mar 13;24(6):5465. doi: 10.3390/ijms24065465.

Abstract

Mitophagy/autophagy plays a protective role in various forms of liver damage, by renovating cellular metabolism linking to sustain liver homeostasis. A characterized pathway for mitophagy is the phosphatase and tensin homolog (PTEN)-induced putative kinase 1 (PINK1)/Parkin-dependent signaling pathway. In particular, PINK1-mediated mitophagy could play an indispensable role in improving the metabolic dysfunction-associated fatty liver disease (MAFLD) which could precede to steatohepatitis (NASH), fibrosis, and hepatocellular carcinoma. In addition, the PI3K/AKT/mTOR pathway might regulate the various characteristics of cellular homeostasis including energy metabolism, cell proliferation, and/or cell protection. Therefore, targeting mitophagy with the alteration of PI3K/AKT/mTOR or PINK1/Parkin-dependent signaling to eliminate impaired mitochondria might be an attractive strategy for the treatment of MAFLD. In particular, the efficacy of prebiotics for the treatment of MAFLD has been suggested to be useful via the modulation of the PI3K/AKT/mTOR/AMPK pathway. Additionally, several edible phytochemicals could activate mitophagy for the improvement of mitochondrial damages, which could also be a promising option to treat MAFLD with providing liver protection. Here, the potential therapeutics with several phytochemicals has been discussed for the treatment of MAFLD. Tactics with a viewpoint of prospective probiotics might contribute to the development of therapeutic interventions.

Keywords: AMPK; MAFLD; NAFLD; PI3K/AKT signaling pathway; ROS; mTOR; mitophagy; prebiotics.

Publication types

  • Review

MeSH terms

  • Humans
  • Mitophagy* / physiology
  • Non-alcoholic Fatty Liver Disease* / drug therapy
  • Phosphatidylinositol 3-Kinases
  • Prebiotics
  • Prospective Studies
  • Proto-Oncogene Proteins c-akt
  • Reactive Oxygen Species / metabolism
  • TOR Serine-Threonine Kinases
  • Ubiquitin-Protein Ligases / metabolism

Substances

  • Prebiotics
  • Phosphatidylinositol 3-Kinases
  • Proto-Oncogene Proteins c-akt
  • Reactive Oxygen Species
  • TOR Serine-Threonine Kinases
  • Ubiquitin-Protein Ligases

Grants and funding

This research received no external funding.